(19)
(11) EP 3 139 745 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.08.2020 Bulletin 2020/35

(45) Mention of the grant of the patent:
08.07.2020 Bulletin 2020/28

(21) Application number: 15789628.3

(22) Date of filing: 08.05.2015
(51) International Patent Classification (IPC): 
A01N 63/00(2020.01)
C12N 15/86(2006.01)
C12N 15/00(2006.01)
(86) International application number:
PCT/US2015/029905
(87) International publication number:
WO 2015/172033 (12.11.2015 Gazette 2015/45)

(54)

VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS

IMPFSTOFFE GEGEN INFEKTIONEN MIT GENITAL-HERPES-SIMPLEX

VACCINS CONTRE LES INFECTIONS DE L'HERPÈS SIMPLEX GÉNITAL


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.05.2014 US 201461990975 P

(43) Date of publication of application:
15.03.2017 Bulletin 2017/11

(60) Divisional application:
20184563.3

(73) Proprietor: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
Baton Rouge, LA 70808 (US)

(72) Inventor:
  • KOUSOULAS, Konstantin
    Baton Rouge, Louisiana 70810 (US)

(74) Representative: Gauchet, Fabien Roland et al
Brandon IP 64, rue Tiquetonne
75002 Paris
75002 Paris (FR)


(56) References cited: : 
WO-A1-92/13943
WO-A2-2008/141151
US-B1- 7 374 768
WO-A1-99/36087
WO-A2-2013/177172
   
  • Brent Stanfield: "Vaccination with the HSV-1 Attenuated Virus VC2 Protects Mice against Lethal Challenge with Virulen HSV-1 and HSV-2 Strains (ID09)", 2013 Southeast Regional IDeA Meeting, 17 November 2013 (2013-11-17), page 51, XP055409749, Retrieved from the Internet: URL:http://se13idea.uams.edu/Proceedings (final 4).pdf [retrieved on 2017-09-25]
  • SAIED ET AL: "A replication competent HSV-1(McKrae) with a mutation in the amino-terminus of glycoprotein K (gK) is unable to infect mouse trigeminal ganglia after cornea infection", CURRENT EYE RESEARCH, INFORMA HEALTHCARE USA, US, vol. 39, no. 6, 1 January 2014 (2014-01-01), pages 596-603, XP008185311, ISSN: 0271-3683, DOI: 10.3109/02713683.2013.855238 [retrieved on 2014-01-08]
  • N. JAMBUNATHAN ET AL: "Site-Specific Proteolytic Cleavage of the Amino Terminus of Herpes Simplex Virus Glycoprotein K on Virion Particles Inhibits Virus Entry", JOURNAL OF VIROLOGY., vol. 85, no. 24, 15 December 2011 (2011-12-15), pages 12910-12918, XP055409910, US ISSN: 0022-538X, DOI: 10.1128/JVI.06268-11
  • FOSTER TIMOTHY P ET AL: "Functional and physical interactions of the herpes simplex virus type 1 UL20 membrane protein with glycoprotein K", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 13, 1 July 2008 (2008-07-01), pages 6310-6323, XP002587598, ISSN: 0022-538X, DOI: 10.1128/JVI.00147-08
  • LYER ET AL.: 'Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.' VIROL J. vol. 10, no. 1, 2013, ISSN 1743-422X page 317, XP055235738
  • SAIED ET AL.: 'A replication competent HSV-1(McKrae) with a mutation in the amino-terminus of glycoprotein K (gK) is unable to infect mouse trigeminal ganglia after cornea infection.' CURR EYE RES. vol. 39, no. 6, pages 596 - 603, XP008185311
  • CHARLES ET AL.: 'Phenylalanine residues at the carboxyl terminus of the herpes simplex virus 1 UL20 membrane protein regulate cytoplasmic virion envelopment and infectious virus production.' J VIROL. vol. 88, no. 13, ISSN 0022-538X pages 7618 - 27, XP055235739
  • STANFIELD ET AL.: 'A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.' PLOS ONE vol. 9, no. 10, 28 October 2014, page E109890, XP055235742
  • J. M. Melancon ET AL: "Genetic Analysis of the Herpes Simplex Virus Type 1 UL20 Protein Domains Involved in Cytoplasmic Virion Envelopment and Virus-Induced Cell Fusion", JOURNAL OF VIROLOGY., vol. 78, no. 14, 15 July 2004 (2004-07-15) , pages 7329-7343, XP55409901, US ISSN: 0022-538X, DOI: 10.1128/JVI.78.14.7329-7343.2004
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).